Evidence map›Paper›PMID 34585359›Full record

ReviewPharmacoEconomics2022

Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates.

Laura C Edney, James Lomas, Jonathan Karnon, Laura Vallejo-Torres, Niek Stadhouders, Jonathan Siverskog, Mike Paulden, Ijeoma P Edoka, Jessica Ochalek

Abstract readReview
In one paragraph

Review in PharmacoEconomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Equitable access to costly new drugs.BMJ (Clinical research ed.) · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany.Applied health economics and health policy · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laura C EdneyFlinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia. laura.edney@flinders.edu.au.ORCID http://orcid.org/0000-0002-2447-4118
James LomasCentre for Health Economics, University of York, Heslington, York, UK.ORCID http://orcid.org/0000-0003-2329-7831
Jonathan KarnonFlinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia.ORCID http://orcid.org/0000-0003-3220-2099
Laura Vallejo-TorresDepartment of Quantitative Methods in Economics and Management, University of Las Palmas de Gran Canaria, Canary Islands, Las Palmas de Gran Canaria, Spain.
Niek StadhoudersIQ Healthcare, Radboud University and Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-7296-2335
Jonathan SiverskogCentre for Medical Technology Assessment, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.ORCID http://orcid.org/0000-0003-4853-5576
Mike PauldenSchool of Public Health, University of Alberta, Edmonton, AB, Canada.ORCID http://orcid.org/0000-0002-0381-5980
Ijeoma P EdokaHealth Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0000-0003-4268-3092
Jessica OchalekCentre for Health Economics, University of York, Heslington, York, UK. jessica.ochalek@york.ac.uk.ORCID http://orcid.org/0000-0003-0744-1178

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many health technology assessment committees have an explicit or implicit reference value (often referred to as a 'threshold') below which new health technologies or interventions are considered value for money. The basis for these reference values is unclear but one argument is that it should be based on the health opportunity costs of funding decisions. Empirical estimates of the marginal cost per unit of health produced by a healthcare system have been proposed to capture the health opportunity costs of new funding decisions. Based on a systematic search, we identified eight studies that have sought to estimate a reference value through empirical estimation of the marginal cost per unit of health produced by a healthcare system for England, Spain, Australia, The Netherlands, Sweden, South Africa and China. We review these eight studies to provide an overview of the key methodological approaches taken to estimate the marginal cost per unit of health produced by the healthcare system with the aim to help inform future estimates for additional countries. The lead author for each of these papers was invited to contribute to the current paper to ensure all the key methodological issues encountered were appropriately captured. These included consideration of the key variables required and their measurement, accounting for endogeneity of spending to health outcomes, the inclusion of lagged spending, discounting and future costs, the use of analytical weights, level of disease aggregation, expected duration of health gains, and modelling approaches to estimating mortality and morbidity effects of health spending. Subsequent research estimates for additional countries should (1) carefully consider the specific context and data available, (2) clearly and transparently report the assumptions made and include stakeholder perspectives on their appropriateness and acceptability, and (3) assess the sensitivity of the preferred central estimate to these assumptions.

Indexed as

Delivery of Health CareTechnology Assessment, BiomedicalBiomedical TechnologyChinaCost-Benefit AnalysisEnglandHumans

Identifiers

PMID34585359
PMCPMC8478606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.